NeoPharm (NEOL) Starts Enrolling Pancreatic Cancer Patients in Phase II Trial of LE-DT
4/20/2010 9:56:39 AM
LAKE BLUFF, Ill.--(BUSINESS WIRE)--NeoPharm, Inc. (Other OTC: NEOL.PK), announced today that it has started enrolling patients in its Phase II clinical trial for liposome entrapped docetaxel (LE-DT), as a frontline treatment of pancreatic cancer patients with locally advanced or metastatic disease. LE-DT is a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®.
comments powered by